United States - English - NLM (National Library of Medicine)

clinical solutions wholesale - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine 2 mg

United States - English - NLM (National Library of Medicine)

cardinal health - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine 2 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - fluphenazine hydrochloride (unii: zou145w1xl) (fluphenazine - unii:s79426a41z) - fluphenazine hydrochloride 5 mg

United States - English - NLM (National Library of Medicine)

clinical solutions wholesale, llc - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine 2 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - fluphenazine hydrochloride (unii: zou145w1xl) (fluphenazine - unii:s79426a41z) - fluphenazine hydrochloride 5 mg

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown hypersensitivity to perphenazine tablets, their components, or related compounds. perphenazine products are also contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic damage, since a hyperthermic reaction with temperatures in excess of 104°f may occur in such patients, sometimes not until 14 to 16 hours after drug administration. total body ice-packing is recommen

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown hypersensitivity to perphenazine products, their components, or related compounds. perphenazine products are also contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic damage, since a hyperthermic reaction with temperatures in excess of 104°f may occur in such patients, sometimes not until 14 to 16 hours after drug administration. total body ice-packing is recommended for such a reaction; antipyretics may also be useful.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown hypersensitivity to perphenazine products, their components, or related compounds. perphenazine products are also contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic damage, since a hyperthermic reaction with temperatures in excess of 104°f may occur in such patients, sometimes not until 14 to 16 hours after drug administration. total body ice-packing is recomme

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown hypersensitivity to perphenazine products, their components, or related compounds. perphenazine products are also contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic damage, since a hyperthermic reaction with temperatures in excess of 104°f may occur in such patients, sometimes not until 14 to 16 hours after drug administration. total body ice-packing is recomme

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - perphenazine (unii: fta7xxy4ez) (perphenazine - unii:fta7xxy4ez) - perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. perphenazine products are contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown hypersensitivity to perphenazine products, their components, or related compounds. perphenazine products are also contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic damage, since a hyperthermic reaction with temperatures in excess of 104°f may occur in such patients, sometimes not until 14 to 16 hours after drug administration. total body ice-packing is recommended for such a reaction; antipyretics may also be useful.